What Verdica's 799 score means for APPCO
APPCO's composite score of 799 out of 850 places it in the "strong" band (740–799), reflecting consistent compliance across the regulatory dimensions Verdica tracks. A score in this range indicates a provider that meets core licensing and operational requirements and demonstrates above-average adherence to FDA and DEA standards. Readers should interpret this as a provider with a solid compliance record, though not yet in the "excellent" tier (800–850), which represents the highest confidence level. The score is built on documented state board licensing records, FDA product and manufacturer data, and DEA oversight—meaning it reflects regulatory reality rather than self-reported metrics. For business owners or consumers evaluating APPCO, this score suggests the provider warrants serious consideration, but due diligence specific to your use case remains important.
How the sub-scores break down
Product Approval (850). This perfect sub-score indicates that all products APPCO distributes or manufactures have passed FDA review and maintain current approval status. In the pharmacy supply chain, a high product approval score reflects no flagged formulations, unlicensed compounds, or recalled items in active inventory records. This is the strongest possible signal for product legitimacy.
Manufacturer Profile (720). This mid-range sub-score suggests APPCO's manufacturing practices and facility compliance meet regulatory baseline requirements but may have minor or historical discrepancies in FDA inspections, quality certifications, or documentation standards. A score of 720 is acceptable but not exemplary; it typically reflects a manufacturer that passes inspections but may not hold premium certifications (such as high-level quality assurance designations) or has resolved past observations from regulators.
FDA Compliance (830). This high sub-score indicates APPCO maintains strong adherence to FDA regulations governing pharmaceutical manufacturing, labeling, distribution, and reporting. An 830 reflects no current warning letters, significant product recalls, or ongoing enforcement actions. Minor historical citations or resolved compliance issues may still exist, but the provider has demonstrated correction and sustained compliance.
What regulators track for pharmacy providers
State boards of pharmacy maintain licensing records, disciplinary histories, and operational permits for all registered entities. Regulators evaluate whether a provider holds valid licensure, has reported ownership changes, and has a clean disciplinary record. Infractions tracked include unlicensed practice, diversion of controlled substances, and failure to maintain required records.
The FDA oversees pharmaceutical product approval, manufacturing standards, and facility inspections under Current Good Manufacturing Practices (CGMP). Regulators assess product applications, post-market safety reporting, and facility compliance. Violations—such as unapproved drug distribution, contamination events, or inadequate quality controls—trigger warning letters, recalls, or enforcement actions that lower scores.
The DEA tracks controlled substance handling, including inventory records, prescriber licensing, and distribution chain integrity. Compliance infractions include diversion, failure to report suspicious orders, and improper record-keeping. DEA audits and inspection findings feed directly into compliance scoring.
Verdica aggregates these three data streams to compute a composite view. A provider with clean state licensing, approved products, and no FDA or DEA enforcement actions scores highest. Historical violations that have been resolved lower scores incrementally; ongoing or unresolved issues trigger steeper penalties.
Bottom line
APPCO's score of 799 positions it as a strong, above-average provider with no apparent significant regulatory red flags. Before committing to a business relationship, confirm that current state pharmacy licenses are active, request copies of recent FDA inspection records, and verify DEA compliance status independently through public databases such as the FDA's CBER and the DEA's Diversion Investigation Unit resources.